Biocon · Analyst questions, management answers, and the quality of the response where the ledger is available.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
29%
Numeric claims
2
Consistency
contradicted
Question ledger
Amey Chalke · Research desk
partialIn the U.S., we have seen that biosimilars have held on to their price, particularly those in the oncology space, for over five years, and this continue to hold value. So there is, of course, a competitive dynamics which will play off, but we expect a much more stable price pricing regimen than the other markets that are there.
Amey Chalke · Research desk
partialYeah, I think the way you would expect is that there will competitive dynamics will play out across markets as product mature. But we really feel that, you know, given the increased market shares, there will be a growth in the products and the revenues. Pricing will, of course, erode over a period of time.
Amey Chalke · Research desk
evasiveI mean, we've not provided any guidance on the numbers at this point, to my knowledge. The way we see this is that, given that for adalimumab, we are in a very good position, that we are integrated.
Tushar Manudhane · Motilal Oswal
evasiveWe, as Peter explained in his opening comments, we did have the inspection from the agency last month, and we are in the process of responding to the agency with a very comprehensive CAPA plan. And that is within the stipulated timeline. So once we've done that, we should be in a position to outline next steps.
Tushar Manudhane · Motilal Oswal
evasiveOn the Malaysia side, we are in the... We have responded to the observations that the agency had made, and we will be looking forward to them scheduling an inspection for us to move forward on that.
Tushar Manudhane · Motilal Oswal
partialIn terms of specific numbers or guidance, in terms of what the growth is, I think it'll be a bit difficult for us to give that. But definitely the first half will continue to be muted, as we have seen in first quarter, but second half, we will see a good growth over first half. Second half will be a significant growth over first half. But the overall year, we still expect like a high single digit kind of growth levels for the business.
Neha Manpuria · BofA
partialI think as, Neha, as Peter outlined in his opening comments, the quarter-on-quarter decline, which you are seeing is, one, is to adjust for the branded formulation business, which is a discontinued business... The other piece, of course, is that, you will see a cyclical nature in terms of, how tenders will open up over the over the different emerging markets.
Neha Manpuria · BofA
evasiveGiven that we are in a litigation right now, Neha, it wouldn't be appropriate to comment on this. I know you made a comment on how the litigation in the district court played out. There were three patents that were litigated. Two were ruled in our favor, one wasn't ruled in our favor, which of course, we will, you know, take up appropriately.
Neha Manpuria · BofA
directSo, Neha, the net debt for BBL is about INR 1.2 billion, slightly higher than INR 1.2 billion. You would see a sequential improvement because of working capital efficiencies, which have come in this quarter.
Surya Patra · PhilipCapital
evasiveI wouldn't speculate which market will open up first, other than the fact that Canada, we have a very clear market entry date, and we are the first to enter there. So that is one clarity. We do not also think, Surya, that, to our knowledge, there are multiple other players who have got approval.
Surya Patra · PhilipCapital
declinedThe first is we've not given guidance in terms of our projections in the past, and we continue to stay with this. It is, it's not advisable to give guidance on market shares. We will let you know as market evolves.
Surya Patra · PhilipCapital
partialYeah, so that we had said it is about 23%, and that's consistent with what we reported last year as well. So I think core EBITDA is healthy at 30%, EBITDA is at 23%. And you can't compare the margins for the last 5 years, because before FY 2023, business was different.
